Showing results (151-160 of 538) with videos related to

Sort By:
Pageof 54
Journal of Autoimmunity|April 26, 2005
CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndromeJacques-Eric Gottenberg, Frédéric Lavie, Karim Abbed, et al.
Rheumatology (Oxford, England)|November 3, 2016
Clinical relevance of RORγ positive and negative subsets of CD161+CD4+ T cells in primary Sjögren's syndromeLinlin Zhao, Gaetane Nocturne, Scott Haskett, et al.
Annals of the Rheumatic Diseases|February 16, 2021
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to considerAlessia Alunno, Aurélie Najm, Xavier Mariette, et al.
European Cytokine Network|March 14, 2007
Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalitiesChristelle Vauloup, Roman Krzysiek, Liliane Greangeot-Keros, et al.
RMD Open|August 29, 2024
Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren's diseaseJustine Luciano, Laurent Gilardin, Gaétane Nocturne, et al.
RMD Open|November 24, 2024
Stability of symptom-based subtypes in Sjogren's diseaseJoe Scott Berry, Jessica Tarn, John Casement, et al.
Journal of Virology|July 16, 2010
Nucleotide variability and translation efficiency of the 5' untranslated region of hepatitis A virus: update from clinical isolates associated with mild and severe hepatitisVincent Mackiewicz, Anne Cammas, Delphine Desbois, et al.
Arthritis Research & Therapy|March 2, 2006
B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndromeMarc Ittah, Corinne Miceli-Richard, Jacques- Eric Gottenberg, et al.
RMD Open|April 9, 2026
Birth length and perinatal exposures and rheumatoid arthritis risk in the E3N cohortPerrine Dusser, Yann Nguyen, Claire Perrin, et al.
RMD Open|September 29, 2017
Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trialJohanna Sigaux, Florian Bailly, David Hajage, et al.
Pageof 54